Antibodies Industry To Rise Up Due To The Increasing Awareness And Adoption Of Personalized Medicine
Grand View Research’s Antibodies industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.
Access the Global Antibodies Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.
Antibody Production Market Growth & Trends
The global antibody production market size is anticipated to reach USD 42.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.92% from 2023 to 2030. Due to the rising incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases, as well as the increased need for therapeutic antibodies the antibody production market is anticipated a significant growth.
Nearly half of all R&D programs related to monoclonal antibodies are allocated for cancer treatment. The focused approach of monoclonal antibodies has transformed cancer treatment by minimizing adverse effects and enhancing patient outcomes. Nevertheless, further research and development are crucial to maximize the effectiveness of antibodies in treating cancer. The market for antibody production is anticipated to experience growth due to the escalated investment in research and development activities, particularly in cancer treatment. Moreover, the demand for personalized medicine, which seeks to offer customized treatments based on an individual's genetic composition, lifestyle, and environmental influences, is anticipated to boost the antibody production market's growth.
Polyclonal Antibodies Market Growth & Trends
The global polyclonal antibodies market size is anticipated to reach USD 2.21 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.01% from 2023 to 2030. The increasing technological advancements in the production of antibodies-based drugs, the growing prevalence of infectious & chronic diseases such as cancer across the globe, and the rising number of biopharmaceutical research and development activities are the main drivers of the industry. In addition, Polyclonal antibodies (pAbs) are extensively utilized in both quantitative and qualitative biological research as well as several diagnostic tests. The use of polyclonal antibodies has had a positive impact on the treatment of COVID-19 patients, with studies showing that these therapies can reduce hospitalization rates and improve outcomes for patients with mild to moderate disease. Additionally, the development of pAbs has helped to advance the understanding of the immune response to COVID-19 and is projected to lead the development of more effective treatments and vaccines in the future. Thus, the COVID-19 pandemic has had a significant impact on the pAbs market.
Monoclonal Antibodies Market Growth & Trends
The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.04% in the forecast period, according to a new report by Grand View Research, Inc. Increasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive the market growth in the forecast period.
The rising demand for personalized medicine is likely to positively affect the development of therapeutic mAb targeted therapies that are tailored to individual requirements. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment, and large-scale production capabilities, as compared to conventional treatment options, and can significantly drive market growth.
Order your copy of Free Sample of “Antibodies Industry Data Book - Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research
Cancer Monoclonal Antibodies Market Growth & Trends
The global cancer monoclonal antibodies market size is expected to reach USD 281.78 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.20% from 2023 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.
Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.
Research Antibodies Market Growth & Trends
The global research antibodies market size is expected to reach USD 2.21 billion by 2030, expanding at a CAGR of 4.76% from 2023 to 2030, according to a new report by Grand View Research, Inc. Factors driving the market include a rise in R&D activities undertaken by biopharmaceutical and biotechnology companies and increase in support from government authorities. Furthermore, expansion in the scope of neurobiology and stem cell research and the availability of technologically advanced antibody production methods are expected to propel market growth.
An increase in the number of collaborative initiatives undertaken by research institutes and various public and private entities for the promotion of cell-based research is fueling market growth. The trend is more prominent in established markets, such as North America, that have an established scientific infrastructure. For instance, in March 2020, the Canadian government invested around USD 4.3 million in funds towards the Centre for Commercialization of Regenerative Medicine, which is involved in carrying out scientific studies based on cell regeneration. Moreover, in April 2021, the government announced an investment of USD 45 million over 3 years in Stem Cell Network to develop information, therapies, and technologies to benefit individuals living with chronic and severe illnesses such as COVID-19 and assess its long-term impact. Such initiatives are expected to encourage further adoption of antibody activities and enhance the growth prospects for the market.
Custom Antibody Market Growth & Trends
The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness substantial growth during the forecast period. This growth is attributed to the increasing fundraising by biotech startups for developing innovative products. Additionally, rising awareness of personalized diagnostic and therapeutic treatments in emerging markets is also a contributing factor to the growth of the custom antibody market.
Increasing investment by the players to expand their services in the development and production of antibodies is likely to support the growth of the market. For instance, Absolute Antibody Ltd. is into the services of custom antibody sequencing, expression, and engineering. In August 2022, the company announced the expansion of its manufacturing facility by increasing the lab space and investing in automated technology such as next-generation sequencing, purification, and expression. The expansion is expected to improve the production workflow for recombinant antibodies.
Go through the table of content of Antibodies Industry Data Book to get a better understanding of the Coverage & Scope of the study.
Mammalian Polyclonal IgG Antibody Market Growth & Trends
The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.67 billion by 2030, registering a CAGR of 5.01% of the overall revenue, according to a new report by Grand View Research, Inc. The industry has witnessed significant growth owing to the development of innovative drugs and increasing government initiatives. Pharma and biotech companies are indulging in rigorous research and development since the antibody-drug conjugate is considered to be the fastest-growing field of the pharmaceutical market.In October 2022, SAB Biotherapeutics announced an exclusive partnership with Emergent BioSolutions Inc. According to the agreement, Emergent BioSolutions is expected to offer end-to-end services of Contract Development and Manufacturing (CDMO) to produce polyclonal antibody-based products.
The partnership will enable SAB Biotherapeutics to primarily focus on the research and development of the polyclonal antibody drug pipeline. As of October 2022, the company is conducting various clinical-stage programs in the treatment of influenza, acute and recurrent C. diff., Type 1 diabetes and researching potential candidates in oncology and immunology. The COVID-19 pandemic surged the use of polyclonal antibodies across the globe. For instance, in July 2022, GigaGen Inc. announced the publication of research showcasing its studies of GIGA-2050, recombinant polyclonal antibodies for COVID-19. According to the research, the GIGA-2050 has an effective manufacturing approach to treating infectious diseases by targeting numerous viral epitopes.
Competitive Landscape
Key players operating in the Antibodies Industry are –
• Danaher Corporation • Thermo Fisher Scientific Inc. • Sartorius AG • GE Healthcare • Eppendorf AG • Merck KGaA • Amgen Inc • Novartis AG • AstraZeneca plc • Abcam plc • F. Hoffman-La Roche Ltd. • Eli Lilly and Company
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Comments